Failure to maintain remission · Participants with Crohn's disease in remission
Adalimumab leads to lower failure to maintain clinical remission compared with placebo (high certainty).
2 findings from 1 review
Failure to maintain endoscopic remission · Participants with Crohn's disease in remission
Adalimumab probably leads to lower failure to maintain endoscopic remission compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · Participants with Crohn's disease in remission
Adalimumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
Adalimumab probably leads to lower serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Participants with Crohn's disease in remission
Adalimumab probably leads to lower withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic response with prior TNF‐α antagonist exposure · Participants with Crohn's disease in remission
Adalimumab probably leads to lower failure to maintain clinical or endoscopic response with prior TNF‐α… compared with placebo (moderate certainty).
1 finding from 1 review
Clinical remission · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement · Patients with ileal pouch‐anal anastomosis
Adalimumab showed no clear difference in clinical improvement compared with placebo (low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
No of episodes of acute pouchitis · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
IBDQ at week 8 · people with active UC
1 finding from 1 review
QoL · people with active UC
1 finding from 1 review
Improved IBDQ at week 8 · people with active UC
Adalimumab probably leads to higher improved IBDQ at week 8 compared with placebo (moderate certainty).
1 finding from 1 review
Improved IBDQ at week 52 · people with active UC
Adalimumab probably leads to higher improved IBDQ at week 52 compared with placebo (moderate certainty).
1 finding from 1 review